Unlocking Success: How Extensive Research Transforms Outcomes
In February 2019, Dan Grunfeld, a 69-year-old chemist from Aurora, Colorado, received a life-altering diagnosis: stage III pancreatic adenocarcinoma. Initially struggling with peripheral neuropathy and persistent health issues, he sought medical attention. After undergoing a series of tests including an ultrasound and a PET/CT scan, the results revealed a blockage in both his pancreatic and bile ducts caused by a tumor on his pancreas.
The Start of a Challenging Treatment Journey
Grunfeld’s treatment plan was devised by Dr. Lillian Klancar at Kaiser Permanente. The strategy included a Whipple procedure, a complex surgery aimed at removing the tumor, followed by FOLFIRINOX chemotherapy. Notably, genetic testing showed no mutations in Grunfeld’s cancer, which can influence treatment options.
- Surgery: Completed in late February 2019
- Chemotherapy: Began in May 2019
Grunfeld chose to prioritize surgery due to the severe blockage of his ducts, which had led to alarming liver values and jaundice. He opted for surgery shortly after receiving a positive biopsy.
Regrettably, his battle with pancreatic cancer was far from over. Nearly four years post-surgery, in October 2022, Grunfeld faced a recurrence of the disease, prompting another round of FOLFIRINOX chemotherapy.
A Scientist’s Approach: Research and Clinical Trials
With a background in chemistry, Grunfeld’s instincts drove him to delve into extensive research about pancreatic cancer. He discovered a promising clinical trial at the University of Virginia focusing on EGFR immunotherapy. Under the guidance of Dr. Lawrence Lum and Dr. Tri Le, Grunfeld participated in a trial involving the collection of his white blood cells to create activated T cells for immunotherapy.
- Trial Name: Phase Ib/II Treatment of Advanced Pancreatic Cancer with Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells
- Coverage: Medicare, along with contributions from UVA and the trial sponsors, helped offset costs.
Despite experiencing severe side effects, including a cytokine reaction that led to intense nausea, Grunfeld persevered through the trial and is now on the mend. His recent checkup revealed excellent blood and PET/CT results, indicating a positive outcome from the trial.
Valuable Lessons from the Cancer Journey
Reflecting on his experience, Grunfeld emphasizes the importance of actively engaging in one’s healthcare. He believes that aligning with supportive doctors and being open to experimental treatments can significantly enhance survival outcomes beyond traditional care.
- Engagement: Take charge of your treatment journey.
- Support: Collaborate with healthcare professionals who resonate with you.
Grunfeld’s story serves as a powerful reminder that each cancer journey is unique. By advocating for oneself and exploring all available options, patients can potentially improve their quality of life and treatment outcomes. Today, Grunfeld continues his work as a chemist, drawing strength from his experiences and maintaining a hopeful outlook on life.
